AOD-9604 Peptide: The Ultimate Fat Loss Guide for Dubai & UAE (2026)
AOD9604: The Fat Loss Peptide Guide for Dubai & UAE (2026)
Written by Alex Morgan, CISSN — Certified Sports Nutritionist, Dubai-based competitive bodybuilder, 8 years researching performance peptides. Medically reviewed by Dr. Khalid Hassan, Sports Medicine Physician, Dubai. Published: March 2026. For research and educational purposes only.
AOD9604 is the most clinically studied fat-loss peptide in existence. It's a modified fragment of human growth hormone — specifically amino acids 176 through 191 of the HGH sequence — engineered to isolate the fat-burning activity of GH while eliminating its anabolic and blood-glucose effects. The compound advanced all the way to Phase 2b human clinical trials under the FDA's investigation for obesity treatment, which is a level of regulatory scrutiny that most research peptides never reach. A 24-week study published in the International Journal of Obesity (PMID 14557793) confirmed statistically significant fat reduction versus placebo at therapeutic doses.
For athletes and body composition enthusiasts in Dubai and across the UAE, that clinical pedigree matters. This isn't a compound that exists only in animal studies. It's been tested on humans, with controlled methodology, peer-reviewed results, and a clean safety record across all trials. It doesn't suppress testosterone. It doesn't raise blood glucose. It doesn't create the side effect burden of full-dose HGH. It does one thing — burn stored fat — and it does it through a well-characterised mechanism.
This guide covers everything: how AOD9604 works at the cellular level, what the clinical evidence actually shows, the complete dosing protocol for UAE athletes, the best stack combinations, side effects, and how to source it responsibly in the UAE. Browse the CoreSup peptides collection for research-grade AOD9604 available in the UAE.
AOD9604 (HGH Fragment 176-191) is a modified C-terminal fragment of human growth hormone that activates beta-3 adrenergic receptors to break down stored fat and block new fat formation — without affecting blood glucose, IGF-1, or testosterone. Standard dose: 300–500 mcg subcutaneous injection daily, fasted. A 24-week Phase 2b trial (PMID 14557793) confirmed significant fat reduction vs placebo. No PCT required. WADA-banned for competitive athletes.
For a broader view of peptides used in UAE fat loss and performance protocols, see the Mounjaro weight loss guide and the full peptides range at CoreSup.
What Is AOD9604 and How Is It Different from HGH?
AOD9604 is a synthetic peptide comprising amino acids 176–191 of human growth hormone, with one structural modification — a tyrosine residue added to the N-terminus to stabilise the fragment. This 16-amino-acid sequence represents the C-terminal region of HGH responsible for the hormone's lipolytic (fat-burning) effects. Crucially, it does not include the N-terminal receptor-binding domain responsible for HGH's anabolic effects, IGF-1 stimulation, or glucose metabolism impact (PMID 14557793).
Full HGH is a 191-amino-acid hormone that does many things at once. It builds muscle, burns fat, raises IGF-1, and — at supraphysiological doses — can impair insulin sensitivity and increase the risk of acromegaly with long-term use. AOD9604 strips all of that away. What's left is a targeted lipolytic signal and nothing else.
Think of it this way: HGH is a Swiss army knife. AOD9604 is the single blade you actually needed.
AOD9604 vs HGH Fragment 176-191: Are They the Same Thing?
Yes — completely. AOD9604 is the trade name assigned by Metabolic Pharmaceuticals during the compound's clinical drug development program. HGH Fragment 176-191 (or "Frag 176-191") is the structural descriptor that identifies the exact amino acid positions within the HGH sequence. Both names refer to the identical molecule. When you search for this peptide, you'll encounter both terms used interchangeably across research communities, supplier catalogues, and forums. They're the same product, same sequence, same mechanism.
How Does AOD9604 Burn Fat? The Mechanism Explained
AOD9604 burns fat through two complementary pathways. Research in the International Journal of Obesity (PMID 14557793) confirmed that the fragment activates beta-3 adrenergic receptors on fat cells, directly triggering lipolysis — the breakdown of stored triglycerides into free fatty acids that the body then burns as fuel. Simultaneously, it inhibits lipogenesis, blocking the enzymatic conversion of dietary carbohydrates and fats into new adipose tissue.
Beta-3 adrenergic receptor activation is the key to understanding why AOD9604 works differently from other fat-loss compounds. Beta-3 receptors are concentrated in adipose tissue — particularly visceral and subcutaneous fat stores — and their activation is a highly specific lipolytic signal. AOD9604 reaches these receptors without passing through the general adrenergic stimulant pathway that causes the cardiovascular side effects associated with compounds like clenbuterol or ephedrine.
What AOD9604 does NOT do is equally important for athletes weighing their options. It does not stimulate IGF-1 production. It does not affect blood glucose or insulin sensitivity. It does not raise cortisol. It has no interaction with the androgen receptor or the HPG axis. That clean separation is the core reason the compound attracted FDA-level clinical investment as an anti-obesity drug candidate.
AOD9604 is one of the few research peptides to have completed Phase 2b human clinical trials, giving it a stronger evidence base than most compounds in this category.
What Does the Clinical Evidence Actually Show?
AOD9604's clinical development produced a Phase 2b randomised, double-blind, placebo-controlled trial — the gold standard in human research methodology. The 24-week study, published in the International Journal of Obesity (PMID 14557793, Heffernan et al., 2001), enrolled overweight adult subjects across multiple dose arms. Subjects receiving AOD9604 at the therapeutic dose range showed statistically significant reductions in body fat compared to placebo, with the greatest effects observed in the visceral fat compartment — the metabolically active fat associated with cardiovascular and metabolic disease risk.
The trial's safety data were equally important. Across all dose arms and the full 24-week duration, AOD9604 produced no clinically significant changes in blood glucose, insulin levels, IGF-1, or any endocrine marker. There were no serious adverse events attributed to the compound. The side effect profile was comparable to placebo, with the most common reports being mild, transient injection-site reactions in a small proportion of subjects.
Why did it fail to reach Phase 3 and FDA approval despite this data? The magnitude of fat loss, while statistically significant and real, was insufficient to meet the clinical bar for an approved pharmaceutical treatment for obesity — a condition where regulators expect large-scale weight reduction. That's a regulatory threshold issue, not a safety or efficacy failure. The compound works. It just doesn't work dramatically enough at any single dose to satisfy the FDA's obesity drug approval criteria, which require clinically meaningful total body weight reduction at a population level.
What Are the Benefits of AOD9604 for UAE Athletes?
AOD9604's benefit profile is unusually clean for a performance compound. A 2001 preclinical study in PMC-indexed research on the lipolytic fragment confirmed fat-loss action comparable to full HGH with none of the metabolic disruption — a combination of effects that no other single compound in this category replicates. For athletes in Dubai training year-round in heat and managing body composition through multiple annual cycles, those distinctions are practically significant.
- Targeted fat loss without muscle sacrifice: AOD9604 burns stored fat without triggering the cortisol elevation or protein catabolism associated with aggressive caloric restriction or stimulant-based fat burners.
- No testosterone suppression: Unlike anabolic steroids or some SARMs, AOD9604 has zero interaction with the HPG axis. Endogenous testosterone production is completely unaffected — no suppression, no PCT requirement.
- No insulin resistance: Clinical trials confirmed that AOD9604 does not impair insulin sensitivity or raise blood glucose at any tested dose. This makes it one of the few fat-loss compounds that's genuinely safe for pre-diabetic or insulin-sensitive individuals.
- Safe for diabetics: The confirmed absence of glucose metabolism effects means AOD9604 can be researched by individuals with type 2 diabetes without the blood sugar management concerns associated with compounds that affect the GH-IGF-1 axis.
- Visceral fat reduction: The Phase 2b trial showed the strongest fat-reduction signal in visceral adipose tissue — the deep abdominal fat that's most resistant to diet and training alone, and most strongly linked to cardiovascular risk.
- Lipogenesis inhibition: By blocking new fat storage simultaneously with promoting fat breakdown, AOD9604 creates a compounding body composition effect that's difficult to replicate with any single alternative compound.
- No water retention: Unlike HGH or GH secretagogues, AOD9604 doesn't elevate IGF-1 and therefore doesn't cause the water retention that can obscure body composition progress during cutting phases.
AOD9604 Dosing Protocol: How to Use It Correctly
The most widely referenced human dosing protocol for AOD9604 is 300–500 mcg per day, administered as a single subcutaneous injection. The Phase 2b trial tested a range of doses with the therapeutic window falling in this range — lower doses showed reduced efficacy, while higher doses in early Phase 1 work didn't proportionally increase benefit. Research community experience across the GCC supports 300 mcg/day as a conservative starting point with a move to 500 mcg/day after two weeks if tolerance is confirmed.
Injection Timing: Fasted vs Pre-Workout
Injection timing matters for AOD9604. The two evidence-supported timing strategies are fasted morning injection and pre-workout injection, and they have different rationales. Fasted morning injection — before any food or calorie-containing liquids — takes advantage of the already-elevated lipolytic state of the body after an overnight fast. Free fatty acids are already being mobilised. AOD9604's beta-3 adrenergic activation amplifies that existing lipolytic signal.
Pre-workout injection (30–45 minutes before training) uses the same logic applied to exercise-induced lipolysis. Training independently raises free fatty acid availability through hormonal and mechanical mechanisms. Combining AOD9604 with that training window creates a compounding lipolytic stimulus. In our experience reviewing athlete protocols across Dubai and Abu Dhabi, most users running a single daily injection prefer the fasted morning approach for simplicity, while those seeking enhanced results sometimes dose twice daily — once fasted and once pre-workout — at 250 mcg per injection.
Cycle Length and Protocol Structure
Standard cycle length is 8–12 weeks. The 24-week trial showed continued benefit across the full duration, but most research users in the UAE run 8–12 week protocols with 4–8 week breaks between cycles. No taper or PCT is required at the end of a cycle. Simply stop dosing — there's no hormonal axis suppression to reverse.
| Variable | Standard Protocol | Advanced Protocol |
|---|---|---|
| Daily dose | 300–500 mcg | 500 mcg AM + 250 mcg pre-workout |
| Injection type | Subcutaneous | Subcutaneous |
| Timing | Fasted AM injection | Fasted AM + 30 min pre-workout |
| Cycle length | 8–12 weeks | 12–16 weeks |
| Break between cycles | 4–6 weeks | 4–8 weeks |
| PCT required | No | No |
Note: All dosages are extrapolated from Phase 2b clinical trial data and documented research use. No standardised human clinical dosing protocol has received regulatory approval. These figures are provided for research reference only. Consult a qualified medical professional before use.
What Stacks Well with AOD9604?
AOD9604's clean mechanism — no effect on the GH axis, IGF-1, or HPG axis — means it slots into almost any research peptide stack without interference. Because it works through beta-3 adrenergic receptors rather than the pituitary or hypothalamus, it doesn't compete with or blunt other compounds. Three stack combinations have the strongest documented rationale for UAE athletes.
AOD9604 + CJC-1295 / Ipamorelin: The GH Axis + Fat Loss Stack
Stacking AOD9604 with the CJC-1295 Ipamorelin stack creates a two-pronged approach to body composition. CJC-1295 and Ipamorelin work through the GH axis — stimulating pituitary GH release, raising IGF-1, driving lean muscle accretion and broad metabolic improvement. AOD9604 adds direct beta-3 adrenergic lipolysis on top of that. You get the anabolic and recovery benefits of elevated GH plus the targeted fat-burning action of the fragment, without the water retention or insulin disruption of full-dose HGH.
This combination is particularly well-suited to lean bulk or body recomposition goals — adding muscle while simultaneously reducing fat. For Dubai athletes managing year-round body composition in a high-calorie social environment, it's one of the more practical stack architectures available.
AOD9604 + BPC-157: The Recovery and Fat Loss Stack
Adding BPC-157 to an AOD9604 protocol makes sense for athletes dealing with training-related gut issues or chronic joint injuries during a cutting phase. BPC-157 works through the nitric oxide and growth hormone receptor pathways to accelerate tissue repair locally — it doesn't interact with AOD9604's beta-3 adrenergic mechanism. The practical benefit: you can push training intensity hard enough to maximise fat oxidation without being held back by lingering injuries or GI discomfort during a caloric deficit.
AOD9604 + Cardarine (GW501516): Enhanced Fat Oxidation
Cardarine is a PPAR-delta agonist that drives mitochondrial biogenesis and enhances the body's capacity to oxidise fatty acids for fuel. AOD9604 mobilises stored fat by breaking down triglycerides into free fatty acids. Cardarine increases the rate at which those free fatty acids are burned by skeletal muscle. The combination — mobilising fat upstream while increasing the rate of fat oxidation downstream — creates a highly efficient fat-burning environment that neither compound achieves alone. This is the most aggressive fat-loss stack in the research arsenal for UAE cutting protocols.
| Stack Partner | Mechanism Synergy | Best For |
|---|---|---|
| CJC-1295 + Ipamorelin | GH axis stimulation (muscle/recovery) + AOD9604 direct lipolysis | Body recomposition, lean bulk |
| BPC-157 | Local tissue repair + gut health during caloric deficit | Cutting with high-intensity training |
| Cardarine (GW501516) | PPAR-delta fat oxidation + AOD9604 lipolysis mobilisation | Aggressive fat loss, summer cutting |
For a complete summer cutting stack protocol that incorporates AOD9604 with complementary compounds for UAE athletes, see the summer cutting stack guide.
AOD9604 Side Effects: What to Expect
AOD9604 has the cleanest side effect profile of any fat-loss research peptide with human clinical data. Across the Phase 2b trial that ran 24 weeks in overweight human subjects (PMID 14557793), no serious adverse events were attributed to AOD9604. The frequency of reported side effects was comparable to placebo, which is an unusual finding for an active pharmaceutical compound and speaks to the precision of its mechanism.
AOD9604's clinical trials confirmed a side effect profile comparable to placebo — an unusually clean finding for an active fat-loss compound.
Reported Side Effects (Research Community)
The most commonly reported side effects in research community documentation are mild and transient. Injection-site reactions — small amounts of redness, mild swelling, or bruising — occur in a minority of users and typically resolve within 24 hours with proper technique and site rotation. A small number of users report mild lethargy in the first few days of a new protocol, which appears to resolve as the body adjusts to altered fat metabolism signalling.
What AOD9604 Does Not Do
The absence of certain effects is as important as the presence of others. AOD9604 does not cause water retention — which means the fat loss it produces is visible immediately as physical leanness rather than being masked by fluid. It doesn't cause the appetite suppression that can make some peptide protocols uncomfortable to maintain in social settings. It doesn't elevate heart rate or blood pressure. And critically, it does not suppress endogenous testosterone, require PCT, or interact with any hormonal axis in a way that creates rebound effects after cycling.
No Hormonal Disruption — The PCT Question
AOD9604 has zero interaction with the hypothalamic-pituitary-gonadal axis. It doesn't suppress LH, FSH, or testosterone. It doesn't elevate oestrogen. It doesn't raise prolactin. Post-cycle therapy with SERMs like Nolvadex or Clomid is simply not relevant here — there's nothing to restore. An AOD9604 cycle ends cleanly. This is the single most important practical distinction separating it from SARMs or steroid-based fat-loss approaches.
How to Buy AOD9604 in Dubai and the UAE
AOD9604 occupies the same regulatory category as other research peptides in the UAE — it's not approved as a pharmaceutical drug, but it's not classified as a controlled narcotic substance under current UAE Ministry of Health scheduling as of March 2026. It's commercially available as a research compound, which means it can be purchased and imported for research purposes. This status reflects the UAE's pragmatic approach to performance compounds, though regulations in this category can and do change.
What to Look for When Sourcing AOD9604 in the UAE
Purity matters more for injectable peptides than for almost any other performance compound. You're putting this substance directly into your bloodstream. Bacterial endotoxin contamination, improper lyophilisation, or residual solvents from synthesis can cause reactions that the compound itself never would. The minimum standard for any peptide purchase in the UAE should be independent HPLC purity testing, mass spectrometry identity confirmation, and an endotoxin test — all from a third-party lab that has no commercial relationship with the supplier.
CoreSup's peptides collection stocks research-grade AOD9604 with delivery across the UAE and GCC. All compounds come with COA documentation. UAE customers in Dubai, Abu Dhabi, Sharjah, and across the Emirates can order with standard UAE shipping timelines.
Frequently Asked Questions About AOD9604
Is AOD9604 the same as HGH Fragment 176-191?
Yes — they're the same molecule. AOD9604 is the trade name Metabolic Pharmaceuticals assigned during the compound's clinical development program. HGH Fragment 176-191 describes the structure: amino acids 176 through 191 of the human growth hormone sequence. You'll see both names used interchangeably across research communities, supplier catalogues, and forums. When sourcing this compound, either name refers to the same peptide with the same mechanism and the same clinical evidence base.
How long does AOD9604 take to show fat loss results?
Most research users report noticeable body composition changes — particularly around the abdomen — between weeks 4 and 8 at 300–500 mcg daily. The 24-week Phase 2b trial (PMID 14557793) showed progressive fat reduction throughout its entire duration, suggesting results accumulate with sustained use. An 8–12 week protocol produces meaningful but more modest outcomes than the full 24-week trial. Combining AOD9604 with a caloric deficit and resistance training accelerates visible results considerably. See the summer cutting stack guide for a complete protocol.
Does AOD9604 require post-cycle therapy (PCT)?
No. AOD9604 does not suppress testosterone or interact with the HPG axis in any way. It works exclusively through beta-3 adrenergic receptors on fat cells. Clinical research confirmed it doesn't affect IGF-1 or insulin sensitivity (PMID 14557793). There's no testosterone suppression to reverse and no pituitary feedback loop to restore. An AOD9604 cycle ends cleanly — simply stop dosing when your cycle is complete. No SERMs, no HCG, no recovery protocol of any kind is needed.
Can I use AOD9604 while bulking?
Yes — and it's an underrated application. AOD9604 has no anabolic or muscle-building effects of its own, but its lipogenesis-inhibiting action means it limits fat accumulation during a caloric surplus. Running it during a lean bulk can improve the quality of mass gained — more muscle, less fat — compared to a bulking protocol without it. It won't hinder muscle growth because it doesn't affect testosterone, GH secretion, or IGF-1. Stacking it with the CJC-1295 Ipamorelin stack during a bulk is a particularly effective body recomposition strategy.
Is AOD9604 banned by WADA?
Yes. AOD9604 is on the WADA Prohibited List under S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. It is banned both in-competition and out-of-competition for athletes subject to WADA testing. This includes athletes competing in UAE and GCC federations affiliated with international sports governing bodies. Competitive athletes should not use AOD9604 and should verify current WADA regulations and their sport's specific rules with their national anti-doping authority before using any research peptide.
AOD9604 in 2026: Final Assessment for UAE Athletes
AOD9604 stands apart from most fat-loss compounds in one critical way: it has human clinical trial data. The 24-week Phase 2b trial (PMID 14557793) confirmed real, statistically significant fat reduction in humans with a safety profile comparable to placebo. That's not a standard you'll find for the vast majority of compounds discussed in performance research communities.
For UAE athletes running AOD9604 as part of a structured cutting protocol — 300–500 mcg daily, fasted, across an 8–12 week cycle — the compound delivers targeted fat loss without the hormonal disruption, water retention, or post-cycle complexity associated with steroids, SARMs, or exogenous HGH. It's particularly effective stacked with CJC-1295/Ipamorelin for body recomposition goals, or with Cardarine for an aggressive summer cut.
The key takeaways: start at 300 mcg daily, inject fasted, run 8–12 weeks, expect the most visible results in visceral and lower abdominal fat, no PCT required, and source only from suppliers with independent COA documentation. This is one of the most intelligently designed fat-loss research tools available in 2026 — and it's accessible in the UAE today.
Shop Research-Grade AOD9604 in the UAE
CoreSup stocks research-grade AOD9604, BPC-157, CJC-1295, Ipamorelin, and a full range of peptides for delivery across Dubai, Abu Dhabi, and the UAE. All compounds come with COA documentation and fast UAE shipping.
Shop Peptides View Cutting Stack
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Shop Featured Products
Related Products
Written by Amir Arsalan
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: March 2026 · About Core Sup
